CAMP4 Therapeutics Corporation
NASDAQ:CAMP · NASDAQ Global Market
+$0.10 today
Vol 0.16M · Avg 0.10M
Cash Flow
Check whether earnings turn into cash
Use operating cash flow, capital spending, free cash flow, and financing activity to see how much value is left for reinvestment or owners.
Free Cash Flow
Net Income to FCF bridge
Analysis
Analysis will appear once cash flow data is available for this period.
Cash Flow Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -$80.4M -55.2% | -$51.8M -5.1% | -$49.3M -11.5% | -$44.2M -57.9% | -$28.0M | $487.6M | $476.4M | $465.2M |
| Depreciation & Amortization | $1.6M -3.4% | $1.7M +1.1% | $1.7M +91.1% | $878.0K -96.1% | $22.8M | $374.2M | $1.2B | $631.8M |
| Deferred Income Tax | $0 | $0 | $0 | $0 | $0 | $1.4B | -$1.5B | $304.2M |
| Stock-Based Compensation | $4.0M -0.8% | $4.0M +38.7% | $2.9M +111.1% | $1.4M -87.8% | $11.3M | $489.0M | $354.6M | -$1.6B |
| Change in Working Capital | $13.0M +790.4% | -$1.9M -1123.4% | -$154.0K -141.3% | $373.0K -76.6% | $1.6M | $350.4M | -$1.6B | $1.5B |
| Accounts Receivables | $0 | $0 | $0 | $0 -100.0% | $1.4M | $592.6M | $1.3B | $626.2M |
| Inventory | $0 | $0 | $0 | $0 -100.0% | $5.2M | $1.0B | $1.2B | $1.1B |
| Accounts Payables | -$1.0M | $0 | $0 | $0 | $0 | $948.2M | -$1.5B | $433.0M |
| Other Working Capital | $14.0M +845.0% | -$1.9M -1123.4% | -$154.0K -141.3% | $373.0K +107.4% | -$5.0M | $567.4M | $1.3B | $601.0M |
| Other Non-Cash Items | $32.2M +1250.3% | $2.4M +238.3% | $705.0K -76.7% | $3.0M +125.3% | -$11.9M | $1.4B | -$1.5B | $300.0M |
| Operating Cash Flow | -$29.6M +35.1% | -$45.6M -3.2% | -$44.2M -14.6% | -$38.5M -813.8% | -$4.2M | $7.2B | $8.9B | $10.5B |
| Capital Expenditures | -$279.0K +36.7% | -$441.0K +35.0% | -$678.0K +83.2% | -$4.0M +69.7% | -$13.3M | $664.0M | $1.4B | $697.6M |
| Acquisitions (Net) | $36.0K | $0 | $0 | $0 | $0 | $937.0M | $1.1B | $1.3B |
| Purchases of Investments | $0 | $0 | $0 | $0 | $0 | $444.2M | $1.4B | $1.3B |
| Sales of Investments | $0 | $0 | $0 | $0 | $0 | $822.2M | $318.2M | -$1.5B |
| Other Investing Activities | $0 | $0 | $0 | $0 -100.0% | $5.7M | $616.4M | $370.0M | $1.2B |
| Investing Cash Flow | -$243.0K +44.9% | -$441.0K +35.0% | -$678.0K +83.2% | -$4.0M +46.9% | -$7.6M | $4.8B | $6.4B | $5.1B |
| Debt Repayment | -$208.0K +74.8% | -$824.0K -810.3% | $116.0K +224.7% | -$93.0K | — | $680.8M | $759.2M | $1.1B |
| Common Stock Issued | $61.2M | $0 | $0 | $0 | $0 | $778.8M | $946.8M | $812.4M |
| Common Stock Repurchased | $0 | $0 | $0 | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $535.2M | $613.6M | $692.0M |
| Other Financing Activities | $14.9M -79.4% | $72.5M +39081.6% | $185.0K -99.8% | $100.3M +3893.0% | -$2.6M | -$1.6B | $1.3B | $1.1B |
| Financing Cash Flow | $75.9M +5.9% | $71.7M +23708.0% | $301.0K -99.7% | $100.2M +3889.5% | -$2.6M | $12.2B | $13.9B | -$15.5B |
| Effect of Forex Changes | $0 | $0 | $0 -100.0% | $25.6M +2753.0% | -$965.0K | $1.3B | $1.1B | $990.2M |
| Net Change in Cash | $46.1M +79.6% | $25.7M +157.6% | -$44.5M -153.5% | $83.2M +640.1% | -$15.4M | $3.2B | $4.9B | $6.5B |
| Free Cash Flow | -$29.8M +35.2% | -$46.0M -2.6% | -$44.8M -5.3% | -$42.6M -143.0% | -$17.5M | $8.6B | -$16.8B | $11.1B |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
ALX Oncology Holdings Inc.
NASDAQ:ALXO
$193.10M
Unicycive Therapeutics, Inc.
NASDAQ:UNCY
$145.60M
Vaxart, Inc.
NASDAQ:VXRT
$135.55M
Repare Therapeutics Inc.
RPTX
$114.24M
MindWalk Holdings Corp.
NASDAQ:HYFT
$70.30M
Biomea Fusion, Inc.
NASDAQ:BMEA
$69.43M
PMV Pharmaceuticals, Inc.
NASDAQ:PMVP
$59.46M
Acrivon Therapeutics, Inc. Common Stock
ACRV
$48.75M
aTyr Pharma, Inc.
ATYR
$45.04M
Quince Therapeutics, Inc.
QNCX
$5.02M
SEC Filings
Recent regulatory filings
No filings found.
Does CAMP generate free cash flow?
CAMP4 Therapeutics Corporation (CAMP) generated -$29,832,000.00 of free cash flow in fiscal 2025.
How much operating cash flow does CAMP produce?
Operating cash flow was -$29,553,000.00, before capital expenditures of $279,000.00.
Explore More
Continue the stock analysis
Jump to another research area for this company.